Keytruda is Called a Blockbuster Drug and Deserves Its Reputation
As reported by the ICIJ, the FDA originally approved Keytruda (pembrolizumab) combined with cisplatin and gemcitabine on October 31, 2023, to treat locally advanced inoperable
Cancer Commons
Cancer Commons
When you have cancer, navigating care can be overwhelming. You may wonder whether you’re on the right path, or if you’re missing out on promising new treatments.
Cancer Commons can help. Our nurse navigators, patient support specialists, PhD scientists, and nationally-recognized oncology experts combine compassion with deep scientific knowledge to help you understand your disease and access your best treatment options.
We draw on the most up-to-date research—as well as insights from leading cancer experts, and outcomes from patients on treatments beyond the standard of care—so you can be confident you’ve left no stone unturned.
Personalized Action Plans
Depending on your needs, we can help:
- Locate clinical trials that may provide access to leading-edge treatments
- Identify and access promising off-label treatments
- Find and access treatments that are available through expanded access or compassionate use
- Identify molecular diagnostic testing to guide treatment
- Explain treatments and tests in plain language
- Make sense of multiple treatment recommendations
- Keep you updated on the latest developments in cancer research
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Patient Worthy Posts on Cancer
The Cancer Dietitian’s Chocolate Avocado Pudding
Editor’s Note: The following recipe was written and shared with us by our friend Julie, the Cancer Dietitian. I cannot tell you how many people
Summary of Grifols’ New Clinical Trials
The pharmaceutical company Grifols—has started dosing patients in the final stage (Phase 3) of two clinical trials. The company is trying to get approval to
Lilly Reports Phase 3 Success for Pirtobrutinib Combination in Relapsed CLL
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent
FDA’s Real-Time Clinical Trial Model: Transforming Oncology Care While Raising New Challenges
As reported on Becker’s Hospital Review, the U.S. Food and Drug Administration’s launch of a real-time clinical trial model marks a notable shift in how
Onchilles Pharma Initiates First-in-Human Trial of N17350 for Advanced Solid Tumors
As reported on Business Wire, Onchilles Pharma has announced the first patient dosing in a Phase 1/2 clinical trial evaluating its investigational therapy, N17350, in
